Clinical Characteristics and Prognostic Impact of Acute Exacerbations in Patients with Interstitial Lung Disease and Lung Cancer: A Single-center, Retrospective Cohort Study

Overview

Journal Thorac Cancer

Specialties Oncology
Pulmonary Medicine

Date 2023 Sep 29

PMID 37772425

Authors

Dong-Gon Hyun

Soo Jin Han

Wonjun Ji

Chang-Min Choi

Jae Cheol Lee

Ho Cheol Kim

Affiliations

Soon will be listed here.

Abstract

Background: Although acute exacerbation (AE) after treatment for lung cancer (LC) is a poor prognostic factor in patients with interstitial lung disease associated with lung cancer (ILD-LC), the risk of AE according to cancer treatment type remains unclear. Therefore, in the present study, we aimed to investigate the association between AE and treatment received for LC in patients with ILD-LC.

Methods: We conducted a retrospective study of patients with ILD-LC who had undergone treatment for LC between January 2018 and December 2022. The primary study outcome was the incidence of AE within 12 months of treatment for LC according to treatment type. The association between AE and all-cause mortality was evaluated as a secondary outcome.

Results: Among a total of 137 patients, 23 (16.8%) developed AE within 12 months of treatment for LC. The incidence of AE according to treatment type was 4.3% for surgery, 16.2% for radiotherapy, 15.6% for chemotherapy, and 54.5% for concurrent chemoradiation therapy (CCRT). Patients who received CCRT were more likely to develop AE, even after adjustment for covariables (hazard ratio [HR], 15.39; 95% confidence interval [CI]: 4.00-59.19; p < 0.001). In addition, AE within 12 months of treatment for LC was associated with an increased risk of all-cause mortality (HR, 2.82; 95% CI: 1.13-7.04; p = 0.026).

Conclusion: Among treatment options for patients with ILD-LC, CCRT was associated with an increased risk for AE. In addition, patients with AE had a higher mortality rate than patients without AE.

Citing Articles

Development of delayed pulmonary toxicities and transcriptional changes in pre-existing interstitial lung disease mice after partial thoracic irradiation.

Fu J, Liu X, Zhou Y, Zhao S, Zeng L, Pan Y Radiat Oncol. 2025; 20(1):20.

PMID: 39920834 PMC: 11806759. DOI: 10.1186/s13014-025-02596-w.

The Between Lung Cancer and Interstitial Lung Diseases: A Focus on Acute Exacerbation.

Zanini U, Faverio P, Bonfanti V, Falzone M, Cortinovis D, Arcangeli S J Clin Med. 2024; 13(23).

PMID: 39685543 PMC: 11641964. DOI: 10.3390/jcm13237085.

Clinical characteristics and prognostic impact of acute exacerbations in patients with interstitial lung disease and lung cancer: A single-center, retrospective cohort study.

Hyun D, Han S, Ji W, Choi C, Lee J, Kim H Thorac Cancer. 2023; 14(33):3323-3330.

PMID: 37772425 PMC: 10665778. DOI: 10.1111/1759-7714.15124.

References

Lee T, Park J, Lee H, Cho Y, Yoon H, Lee J . Lung cancer in patients with idiopathic pulmonary fibrosis: clinical characteristics and impact on survival. Respir Med. 2014; 108(10):1549-55. DOI: 10.1016/j.rmed.2014.07.020. View

Kreuter M, Ehlers-Tenenbaum S, Schaaf M, Oltmanns U, Palmowski K, Hoffmann H . Treatment and outcome of lung cancer in idiopathic interstitial pneumonias. Sarcoidosis Vasc Diffuse Lung Dis. 2015; 31(4):266-74. View

Patel N, Kulkarni T, Dilling D, Scholand M . Preoperative Evaluation of Patients With Interstitial Lung Disease. Chest. 2019; 156(5):826-833. DOI: 10.1016/j.chest.2019.05.028. View

Miyashita K, Kono M, Saito G, Koyanagi Y, Tsutsumi A, Kobayashi T . Prognosis after acute exacerbation in patients with interstitial lung disease other than idiopathic pulmonary fibrosis. Clin Respir J. 2020; 15(3):336-344. DOI: 10.1111/crj.13304. View

Hubbard R, Venn A, Lewis S, Britton J . Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am J Respir Crit Care Med. 2000; 161(1):5-8. DOI: 10.1164/ajrccm.161.1.9906062. View

Naccache J, Gibiot Q, Monnet I, Antoine M, Wislez M, Chouaid C . Lung cancer and interstitial lung disease: a literature review. J Thorac Dis. 2018; 10(6):3829-3844. PMC: 6051867. DOI: 10.21037/jtd.2018.05.75. View

Fisher D, Murphy M, Montesi S, Hariri L, Hallowell R, Keane F . Diagnosis and Treatment of Lung Cancer in the Setting of Interstitial Lung Disease. Radiol Clin North Am. 2022; 60(6):993-1002. PMC: 9969995. DOI: 10.1016/j.rcl.2022.06.010. View

Okamoto T, Gotoh M, Masuya D, Nakashima T, Liu D, Kameyama K . Clinical analysis of interstitial pneumonia after surgery for lung cancer. Jpn J Thorac Cardiovasc Surg. 2004; 52(7):323-9. DOI: 10.1007/s11748-004-0063-6. View

Zhang T, Shen P, Duan C, Gao L . KL-6 as an Immunological Biomarker Predicts the Severity, Progression, Acute Exacerbation, and Poor Outcomes of Interstitial Lung Disease: A Systematic Review and Meta-Analysis. Front Immunol. 2021; 12:745233. PMC: 8699527. DOI: 10.3389/fimmu.2021.745233. View

10.

Long K, Suresh K . Pulmonary toxicity of systemic lung cancer therapy. Respirology. 2020; 25 Suppl 2:72-79. DOI: 10.1111/resp.13915. View

11.

Richeldi L, Cottin V, du Bois R, Selman M, Kimura T, Bailes Z . Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS(®) trials. Respir Med. 2016; 113:74-9. DOI: 10.1016/j.rmed.2016.02.001. View

12.

Sato T, Teramukai S, Kondo H, Watanabe A, Ebina M, Kishi K . Impact and predictors of acute exacerbation of interstitial lung diseases after pulmonary resection for lung cancer. J Thorac Cardiovasc Surg. 2013; 147(5):1604-1611.e3. DOI: 10.1016/j.jtcvs.2013.09.050. View

13.

Tasaka Y, Honda T, Nishiyama N, Tsutsui T, Saito H, Watabe H . Non-inferior clinical outcomes of immune checkpoint inhibitors in non-small cell lung cancer patients with interstitial lung disease. Lung Cancer. 2021; 155:120-126. DOI: 10.1016/j.lungcan.2021.03.014. View

14.

Frank A, Dagogo-Jack I, Dobre I, Tait S, Schumacher L, Fintelmann F . Management of Lung Cancer in the Patient with Interstitial Lung Disease. Oncologist. 2022; 28(1):12-22. PMC: 9847545. DOI: 10.1093/oncolo/oyac226. View

15.

Yamaguchi S, Ohguri T, Ide S, Aoki T, Imada H, Yahara K . Stereotactic body radiotherapy for lung tumors in patients with subclinical interstitial lung disease: the potential risk of extensive radiation pneumonitis. Lung Cancer. 2013; 82(2):260-5. DOI: 10.1016/j.lungcan.2013.08.024. View

16.

Miyazaki K, Kurishima K, Kagohashi K, Kawaguchi M, Ishikawa H, Satoh H . Serum KL-6 levels in lung cancer patients with or without interstitial lung disease. J Clin Lab Anal. 2010; 24(5):295-9. PMC: 6647714. DOI: 10.1002/jcla.20404. View

17.

Kolb M, Bondue B, Pesci A, Miyazaki Y, Song J, Bhatt N . Acute exacerbations of progressive-fibrosing interstitial lung diseases. Eur Respir Rev. 2018; 27(150). PMC: 9488799. DOI: 10.1183/16000617.0071-2018. View

18.

Wang Y, Miao L, Hu Y, Zhou Y . The Efficacy and Safety of First-Line Chemotherapy in Patients With Non-small Cell Lung Cancer and Interstitial Lung Disease: A Systematic Review and Meta-Analysis. Front Oncol. 2020; 10:1636. PMC: 7506119. DOI: 10.3389/fonc.2020.01636. View

19.

Kobayashi H, Naito T, Omae K, Omori S, Nakashima K, Wakuda K . Impact of Interstitial Lung Disease Classification on the Development of Acute Exacerbation of Interstitial Lung Disease and Prognosis in Patients with Stage III Non-Small-Cell Lung Cancer and Interstitial Lung Disease Treated With Chemoradiotherapy. J Cancer. 2018; 9(11):2054-2060. PMC: 5995939. DOI: 10.7150/jca.24936. View

20.

Zhang M, Fan Y, Nie L, Wang G, Sun K, Cheng Y . Clinical Outcomes of Immune Checkpoint Inhibitor Therapy in Patients With Advanced Non-small Cell Lung Cancer and Preexisting Interstitial Lung Diseases: A Systematic Review and Meta-analysis. Chest. 2022; 161(6):1675-1686. DOI: 10.1016/j.chest.2021.12.656. View